Two threshold levels of vitamin D and the prevalence of comorbidities in outpatients of a tertiary hospital.
Osteoporos Int. 2017 Nov 15. doi: 10.1007/s00198-017-4299-2. [Epub ahead of print]
Furuie IN1, Mauro MJJ1, Petruzziello S1, Riechi SC2, Petterle RR3, Boguszewski CL4, Borba VZC5.
|20-30 ng||30-50 ng|
|Anemia||6% of patients||1% of patients|
|Urinary tract disease||11%||5%|
|Avg Vit D||25 ng||37 ng|
|Total number |
- 500 patients in a hospital in Brazil, age: mid 50’s
- This kind of analysis would not be possible in most countries of the world, as they lack enough people with > 30 ng of vitamin D
- Health Problems and D left hand column of most pages
- Incidence of 22 health problems related to vitamin D have doubled in a decade
- Diseases which are related due to vitamin D deficiency
- A doctor becomes aware of vitamin D deficiency in Brazil, a sunny country – June 2014
- Increased number of health risk factors greatly increases number of chronic conditions (related to Vitamin D) – Dec 2017
- Seniors who feel healthier have higher levels of vitamin D (30 ng) – Nov 2016
- Chance of having more than one disease (multimorbidity) up 34 percent if low vitamin D – Sept 2015
- Health Problems and Vitamin D - association, prevention, and treatment has the following chart
This study evaluated the number of comorbidities between two normal values of 25OHD in outpatients during 1 year of 25OHD measurements. Five hundred twenty-nine outpatients were included, patients with 25OHD ≥ 20 and < 30 ng/mL had the higher number of comorbidities, suggesting that for this specific population, 25OHD ≥ 30 ng/mL would be more appropriate.
INTRODUCTION : This study evaluated the comorbidities between two values of 25OHD in outpatients of a tertiary hospital.
METHODS: This is a cross-sectional study with measures of 25OHD in 1-year period, excluding 25OHD < 20 and > 50 ng/mL, clinical research participants, and liver disease and chronic renal failure patients. Patients were divided into two groups: group 1 (G1), 25OHD ≥ 20 and < 30 ng/mL; and group 2 (G2), 250HD ≥ 30 and ≤ 50 ng/mL. Medical records were reviewed for demographic, laboratory, and comorbidity data.
RESULTS: From 529 outpatients included, 319 were in G1 (53.3 ± 15.8 years, 85% women), mean 25OHD 24.8 ± 2.8 ng/mL; and 210 outpatients in G2 (56.7 ± 16.0 years, 83% women), mean 25OHD was 36.8 ± 4.8 ng/mL. G1 had the higher number of comorbidities, including altered glycemia, dyslipidemia, hypothyroidism, urinary tract diseases, arthropathy, secondary hyperparathyroidism, anemia, and neurological and psychiatric disorders. Osteoporosis and hypothyroidism were more prevalent in G2. After binary logistic regression, the variables age (OR 0.988, CI 0.97-1.00, p = 0.048), osteoporosis (OR 0.54, CI 0.36-0.80, p = 0.003), dyslipidemia (OR 1.61, CI 1.10-2.39, p = 0.015), arthropathy (OR 2.60, CI 1.40-5.10, p = 0.003), anemia (OR 15.41, CI 3.09-280.08, p = 0.008), and neurological and psychiatric diseases (OR 3.78, CI 1.98-7.88, p = 0.001) maintained significance.
CONCLUSION: Patients with serum 25OHD ≥ 20 and < 30 ng/mL had higher prevalence of comorbidities compared to ≥ 30 ng/mL.
PMID: 29143130 DOI: 10.1007/s00198-017-4299-2